Marksans Pharma Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/32m2yaekj4ruz3gryfa0o42r.pdf

Key Takeaways


U.S. Performance & Order Book

Mark Saldanha: "Although we were not impacted by tariffs, but there has been a, I think it has basically put an ease to the uncertainty that prevailed in customers or consumers or clients' minds, right? So that is a big plus point that one could take away from this."

U.K. & Europe: Stabilization and Expansion

Mark Saldanha: "I think 2026 will be a turning point where that is concerned. So we are quite hopeful that 2026, we may see a couple of M&As happening out there."

Margin Walk & Cost Structure


Teva Facility & Capacity

Mark Saldanha: "Operating leverage is very visible because of the Teva facility. We are trending around INR 560 crores to INR 600 crores odd from the Teva facility. Our objective was to hit about INR 800 crores odd."

New Geographies & Subsidiaries


Guidance & Commitments

CommitmentSpecificsTimeline
U.S. revenue growth~20% growth achievableUpcoming financial year (FY27)
U.S. order book conversionCurrent $220 mn+ order book begins trending into P&LQ1 or Q2 of next financial year
Employee cost to revenueRevert to 13–13.5% (from ~15%)By Q2 of next financial year
R&D to sales ratio2.5% to 3%Next financial year
Revenue milestoneINR 4,000 crores (current portfolio only, excluding EU/Canada)FY28 or FY29
U.S. order book milestone$300 millionBy FY28
Teva facility revenue~INR 800 croresNo date given; trending at INR 560–600 cr
Europe M&AA couple of transactions possible; 2026 a turning point2026

Key Metrics

MetricQ3 FY26
Operating revenue₹754 cr, +10.6% YoY, all-time high for the quarter
U.S. & North America revenue₹411.9 cr, +24.2% YoY, driven by volumes and seasonal demand
U.K. & EU revenue₹258.2 cr, flat YoY
Australia & New Zealand revenue₹61.4 cr, +30.1% YoY
Rest of World revenue₹22.4 cr
Gross margin58.1%, +184 bps YoY from 56.2%, driven by raw material softening, favourable product mix and forex benefits
EBITDA₹160.7 cr, +23.2% YoY
EBITDA margin21.3%, +217 bps YoY and +125 bps QoQ
Profit after tax₹113.7 cr, +8.2% YoY
EPS₹2.5
9M FY26 operating revenue₹2,094.8 cr, +9.4% YoY
9M FY26 EBITDA margin19.4%, vs 21.2% in 9M FY25, reflecting weaker Q1, higher employee expenses and integration costs
9M FY26 PAT₹271 cr; EPS ₹6.0
U.S. order book$220 million plus
Teva facility revenue₹560–600 cr trending, objective to reach ~₹800 cr
Cash balance₹824.2 cr as of 31st December 2025, debt-free
9M FY26 cash from operations₹263.2 cr
9M FY26 capex₹97 cr
Working capital151 days
9M FY26 R&D spend₹62 cr, 3% of consolidated revenue
Employee cost impact from new labour code₹2.8 cr one-time impact on gratuity and new pay
Employee cost as % of revenue~15%, up from 13% in FY23, driven by Goa facility hiring at ~50% utilization
U.K. filings pace4–5 products per month
U.S. ANDA filings pace7–8 ANDAs per year
Canada portfolio mix80% OTC, 20% Rx
Europe portfolio mix~90% Rx, ~10% OTC
Revenue milestone target₹4,000 cr in next 2–3 years, FY28 or FY29
U.S. order book target by FY28$300 million (per management discussion)
U.S. revenue growth outlook~20% in upcoming financial year, management said "very close to that"
Regular annual capex₹50–60 cr on optimizations; new plant capex could be ₹150–200 cr if triggered
Cash split~50% India books, ~40% U.K. books, rest across U.S. and Australia
Reclassification impact~₹8 cr reclassified from other income to other expenditure in base quarter for mark-to-market forex provision